Bank of America Boosts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $31.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price lifted by Bank of America from $30.00 to $31.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

SNDX has been the topic of a number of other research reports. Jefferies Financial Group initiated coverage on shares of Syndax Pharmaceuticals in a report on Friday, June 28th. They issued a buy rating and a $37.00 price objective on the stock. HC Wainwright upped their price target on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a buy rating in a research note on Thursday. Barclays lifted their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an overweight rating in a research note on Thursday. JPMorgan Chase & Co. cut their target price on Syndax Pharmaceuticals from $34.00 to $33.00 and set an overweight rating on the stock in a research note on Tuesday, August 6th. Finally, Citigroup reduced their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a buy rating for the company in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $35.33.

Syndax Pharmaceuticals Stock Down 0.2 %

NASDAQ SNDX opened at $19.93 on Thursday. The firm has a market capitalization of $1.70 billion, a PE ratio of -6.19 and a beta of 0.94. The stock’s 50 day moving average is $21.22 and its 200 day moving average is $21.69. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. The company’s quarterly revenue was up 3499999990.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.64) EPS. On average, research analysts anticipate that Syndax Pharmaceuticals will post -3.64 earnings per share for the current year.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan acquired 1,250 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Friday, June 14th. The stock was bought at an average cost of $20.03 per share, for a total transaction of $25,037.50. Following the acquisition, the chief financial officer now owns 52,623 shares of the company’s stock, valued at $1,054,038.69. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. bought a new stake in Syndax Pharmaceuticals in the 2nd quarter worth approximately $27,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the second quarter worth $33,000. CWM LLC grew its holdings in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after acquiring an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at $37,000. Finally, Quadrant Capital Group LLC lifted its holdings in Syndax Pharmaceuticals by 158.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after acquiring an additional 1,496 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).